Healthcare
AI in pharma market to hit $28.6b by 2034 on drug discovery push
AI in pharma market to hit $28.6b by 2034 on drug discovery push
Asia Pacific is set to post the fastest growth.
5 days ago
Gene editing market may nearly triple to $30.5b by 2033
Asia Pacific is seen as fastest-growing region.
6 days ago
Biologics boom pushes biopharma equipment market toward $116.4b
Asia-Pacific is emerging as the fastest-growing region.
6 days ago
Ageing, chronic diseases push APAC medtech towards $132b by 2030
Despite this, few companies in the region have scaled globally.
6 days ago
India rolls out terminology, drug registry
The terminology service will be set up for consistent interpretation and exchange of health data.
AI-powered microscopy software poised for $3.09b surge by 2031
North America accounted for the largest market share in 2025.
China’s healthcare defies Hang Seng slump with 0.9% gain
Investor sentiment, however, weakened during the second quarter.
Abu Dhabi and MIT Koch advance AI-driven cancer research
It includes physician-scientist fellowships.
Biomarkers market to top $112b by 2031 on drug discovery demand
Consumables held the largest share at 73.4% in 2025.
AU’s Royal North Shore expands cancer trials access with new unit
It was funded by a $13.8m (AU$20m) gift.
Taiwan's NTUH, EVA Air launch in-flight doctor programme
Physicians recommend scheduling a consultation four to six weeks before departure.
Singapore's CGH cuts desflurane, slashes emissions
Desflurane usage fell to just 1.44 litres in 2025 from 242 litres in 2019.
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings
Hong Kong’s listing pathways provide issuers with flexibility and access to a sophisticated investor base.
Seoul St. Mary's Hospital, Dankook University centres team up on health tech prototypes
They will reduce prototyping time and costs.
Indonesia anchors Longevity 5.0 amidst regional stem cell gaps
Borderless Healthcare links regenerative medicine with clinics, resorts, and home-based wellness.
RESILIA valves reshape lifetime care planning
Durability data and transcatheter reintervention options are influencing treatment decisions across Asia-Pacific
Tissue valve uptake hinges on data and diagnosis
Durability evidence is shifting younger patient use whilst awareness remains Australia’s main adoption barrier.
Most Read
1. IHH Singapore goes preventive with new Healthspan programme 2. Health ministry unveils homegrown AI model built for patients 3. Australia funds $10.4m RNA lung therapy trials at Monash 4. Indonesia bets on stem cell rules to boost longevity care 5. AI in pharma market to hit $28.6b by 2034 on drug discovery pushResource Center
Read Here
Advertise
Sign Up
Partner Events
Event News
Demand was strong for AI-driven and digital healthcare solutions.
Commentary
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings
Beyond symptom control: Redefining IMID care in Malaysia
How decentralised clinical trials can unlock Asia's research potential